These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 14599854

  • 41. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
    Diao L, Hang Y, Othman AA, Nestorov I, Tran JQ.
    Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. The fractional excretion of soluble interleukin-2 receptor-alpha is an excellent predictor of the interleukin-2 receptor-alpha status after treatment with daclizumab.
    ter Meulen CG, Jacobs CW, Wetzels JF, Klasen IS, Hilbrands LB, Hoitsma AJ.
    Transplantation; 2004 Jan 27; 77(2):281-6. PubMed ID: 14742994
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
    Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J.
    N Engl J Med; 1998 Jan 15; 338(3):161-5. PubMed ID: 9428817
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Monitoring of T-cell subsets in patients treated with anti-CD 25 antibody.
    Praditpornsilpa K, Avihingsanon Y, Kupatawintu P, Songpanich S, Pisitkul T, Kansanabuch T, Eiam-Ong S, Chusil S, O-Charoen R, Tungsanga K.
    Transplant Proc; 2004 Mar 15; 36(2 Suppl):487S-491S. PubMed ID: 15041394
    [Abstract] [Full Text] [Related]

  • 48. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG.
    Neurology; 2007 Aug 21; 69(8):785-9. PubMed ID: 17709711
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Daclizumab: a potential asthma therapy?
    Antoniu SA.
    Recent Pat Inflamm Allergy Drug Discov; 2010 Nov 21; 4(3):214-21. PubMed ID: 20804450
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.